The drug development industry has seen a major shift of clinical activity away from large pharmaceutical companies in favour of therapies developed by biotechs and small-to-mid-sized biopharmas. From the 53 new treatments approved in 2020...
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion...
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on...
Asia-Pacific biotech specialist CRO Novotech has released a new webinar about the advantages of conducting...
There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific....
The leading Asia-Pacific biotech specialist CRO Novotech is releasing a series of webinars about the advantages of conducting clinical trials in the Asia-Pacific. Sites across the APAC region have quickly…
Many countries in the Asia-Pacific region are now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment and vaccine candidates. The South Korean Ministry of Food and…
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the global COVID-19 crisis. According to their data, the top 10…
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral infections.
Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments in Asia’s clinical outsourcing landscape. The report highlights the main…
The alliance of regional specialists can provide the best of all worlds: global coverage, regional specialisation and mid-sized CRO flexibility.
© Copyright Verdict Media Limited 2021
